Abstract
Background
Study Design
Results
Conclusions
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionReferences
- The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France.J Womens Health Gend Based Med. 1999; 8: 1052
- Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behavior.J Reprod Med. 1988; 33: 340-346
- Diagnostic and Statistical Manual of Mental Disorders. 2000: 771-774
- Burden of premenstrual dysphoric disorder on health-related quality of life.J Womens Health (Larchmt). 2008; 17: 113-121
- Treatment of premenstrual disorders.J Reprod Med. 2006; 51: 359-370
- Oral contraceptives containing drospirenone for premenstrual syndrome.Cochrane Database Syst Rev. 2009; (CD006586)
- Selective serotonin reuptake inhibitors for premenstrual syndrome.Cochrane Database Syst Rev. 2009; (CD001396)
- Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen.Contraception. 2009; 80: 245-253
- Daily Record of Severity of Problems (DRSP): reliability and validity.Arch Womens Ment Health. 2006; 9: 41-49
- The work limitations questionnaire.Qual Life Newsl. 2002; 28: 9-10
- Selective serotonin reuptake inhibitors and initial oral contraceptives for treatment of PMDD: effective but not enough.CNS Spectr. 2008; 13: 293-300
- Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo.Psychopharmacology (Berl). 2001; 155: 292-298
- Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder.Obstet Gynecol. 2002; 100: 1219-1229
- Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?.CNS Drugs. 2006; 20: 523-547
- Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder.Neuropsychopharmacology. 2007; 32: 153-161
- Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial.Contraception. 2009; 80: 504-511
- Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: Phase 3 study results.Contraception. 2006; 74: 439-445
Article info
Publication history
Footnotes
���Clinical trial registration: ClinicalTrials.gov, NCT00128934.
������Source of financial support: This study was sponsored by Wyeth, which was acquired by Pfizer, Inc., in October 2009.
���Data presentation: 64th Annual Meeting of the American Society of Reproductive Medicine, San Francisco, CA; November 8���12, 2008.
������Financial disclosures: Dr. Halbreich is president and chief executive officer of and holds equity in IN-CLINE RE&D and has received grant support from Corcept, Eli Lilly Labs and Wyeth (acquired by Pfizer, Inc., in October 2009). Dr. Freeman has received research support from Wyeth (acquired by Pfizer, Inc., in October 2009); Pfizer, Inc.; and Xanodyne Pharmaceuticals, and honoraria for consulting and presenting for Wyeth (acquired by Pfizer, Inc., in October 2009), Forest Pharmaceuticals, Pherin Pharmaceuticals and Bayer HealthCare Pharmaceuticals. Dr. Rapkin has received research support from Wyeth (acquired by Pfizer, Inc., in October 2009) and is a��consultant to Bayer Health Care Pharmaceuticals. Dr. Cohen has received research support from National Alliance for Research on Schizophrenia and Depression (past); Astra-Zeneca Pharmaceuticals; Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb; Eli Lilly & Company (past); Forest Laboratories, Inc.; GlaxoSmithKline; National Institute on Aging; National Institutes of Health; National Institute of Mental Health; Ortho-McNeil Janssen; Pfizer, Inc.; Sepracor, Inc. (past); Stanley Foundation (past); and Wyeth (acquired by Pfizer in October 2009) (past). He has been a consultant/advisor for or received honoraria from Eli Lilly & Company (past); Forest Laboratories, Inc. (past); GlaxoSmithKline (past); JDS/Noven Pharmaceuticals; PamLab LLC; Pfizer, Inc. (past); Sepracor, Inc. (past) and Wyeth (acquired by Pfizer in October 2009) (past). Dr. Bergeron has no conflict of interest. Drs. Grubb and Constantine were employees of Wyeth Research (acquired by Pfizer, Inc., in October 2009) at the time of the study. Dr. Mirkin and Ms. Smith are employees of Pfizer, Inc.
